TWI670071B - Composition for promoting hair growth or promoting hair cell growth and use thereof - Google Patents

Abstract

The present invention provides a composition for promoting hair growth or promoting hair cell growth, comprising a multi-peptide composition and a fat-soluble compound, wherein the fat-soluble compound is adiponectin or vitamin D3; The volume percentage of the substance is 1% to 20% multipeptide composition, the adiponectin is 0.1 ng/ml to 100 ng/ml per ml, and the vitamin D3 is 1 nanomolar concentration (nM) to 1000 nM. The present invention further provides the use of the aforementioned composition for the preparation of a medicament for promoting hair growth or promoting hair cell growth, wherein an effective amount of the medicament is administered to a recipient to promote hair growth of the recipient or to promote hair cell growth. In order to solve the problem of the ineffectiveness of the existing drugs for treating hair loss.

Description

Composition for promoting hair growth or promoting hair cell growth and use thereof

The present invention relates to a composition for promoting hair growth, and particularly to a composition comprising a multi-peptide composition and a fat-soluble compound, wherein the fat-soluble compound is adiponectin or vitamin D3; the present invention further relates to a combination of the foregoing Use of the medicament for the preparation of a medicament for promoting hair growth; the invention further relates to the use of a composition as described above for the preparation of a medicament for promoting hair cell growth.

Hair loss is divided into two types: congenital and acquired. Congenital conditions are found in genetic factors. Acquired factors occur in neurological diseases, endocrine diseases, hair follicle blood flow reduction, aging and other physical factors, plus increased stress and lifestyle changes. Both cause the cause of hair loss.

Minoxidil (MNX) is known to act on hair follicle dermal papilla cells, which promotes cell growth and activates hair follicle cells (see J. Invest. Dermatol., 117, 2001, p .1594-1600). Minoxidil has been approved by the US Food and Drug Administration for males and females, with one-third of males and female males with baldness producing visible hair growth, and one-third of patients producing subtle Hair growth, and the remaining one-third of the patients did not produce hair growth, so minoxidil still failed to achieve satisfactory results.

In order to improve, it is necessary to study how to promote hair growth or promote hair cell growth, and the prior art needs to be improved.

In order to overcome the disadvantages of the prior art, it is an object of the present invention to provide a composition which can effectively achieve an effect of promoting hair growth or promoting hair cell growth.

In order to achieve the above object, the technical means employed by the present invention is to provide a composition for promoting hair growth comprising a multi-peptide composition and adiponectin; wherein the multi-peptide composition has a volume percentage of 1% Up to 20% multipeptide composition, the adiponectin is from 0.1 ng (ng/ml) to 100 ng/ml per ml.

Preferably, the multi-peptide composition is selected from the group consisting of angiogenin, platelet-derived growth factor (PDGF), and fibroblast growth factor 7 (FGF7). ) and a group of its combinations.

Preferably, the composition comprises 10% by volume of a multi-peptide composition and 1 ng/ml of adiponectin.

Preferably, the multi-peptide composition is prepared by the following preparation method: preparing a umbilical cords tissue; rinsing the pig umbilical cord tissue with a rinsing liquid to completely separate the blood cells or body fluid from the umbilical cord tissue of the pig Removing; separating cells from pig umbilical cord tissue for subculture to obtain cytokines; freezing and thawing cytokines and cells at least twice to obtain a multi-peptide mixed solution; and mixing the multi-peptide The solution is concentrated to remove salt to obtain a multi-peptide composition wherein the multi-peptide composition has a molecular weight greater than 3000 Daltons (Da).

According to the present invention, "flushing solution" as used herein refers to a solution which is isotonic to the umbilical cord tissue of a pig; preferably, the rinsing liquid is a 90% sodium chloride solution or a phosphate buffered solution. PBS).

According to the present invention, "isolated cells" as used herein refers to a piece of pig umbilical cord cut into pieces of about 0.1 cubic millimeters (mm ³ ) to 100 mm ³ into 6 pieces of umbilical cord pieces placed in a petri dish, including 10 in the culture dish. Milliliter (ml) of medium [α-minimum essential medium (α-MEM) and 10% fetal bovine serum (FBS)], and placed in a constant temperature container for 10 days before removing the umbilical cord Fragments, and 3 ml (ml) of medium were added twice a week, wherein the constant temperature container refers to a carbon dioxide (CO ₂ ) incubator (containing 5% CO ₂ ) to obtain cells.

According to the present invention, "subculture" as used herein means that when the cells are grown to a high density, the cells are collected, and after dilution, are colonized into a new culture dish to reduce cell density and maintain cell growth. The ratio varies depending on the cell type.

According to the present invention, the "freeze-thaw cycle" as used herein refers to freezing cells and their cytokines in liquid nitrogen, and then taking the cells out to room temperature for melting, and repeatedly to achieve the effect of destroying the cell membrane. As exemplified in the present case, the cryotube containing the cells is directly immersed in liquid nitrogen, and the cryotube containing the cells is taken out from the liquid nitrogen and thawed in a 37 ° C water bath, and the above steps are repeated at least twice, and The ruptured cells were centrifuged at 1000 G for 15 minutes to 20 minutes.

According to the present invention, "concentrated desalted" as used herein refers to the effect of placing a multi-peptide mixed solution in a filtration device, and centrifuging and removing the supernatant to concentrate and remove salts of the multi-peptide mixed solution. As exemplified in the present invention, the multi-peptide mixed solution is placed in an ultrafiltration device or a centrifugal device to reduce the volume of the multi-peptide mixed solution, increase the concentration, and remove impurities (salts), and obtain a composition, and the combination The molecular weight of the substance is greater than 3000 Daltons.

Preferably, in the step of separating cells from pig umbilical cord tissue for subculture and obtaining cytokines, the isolated cells are cultured in serum-free medium for 3 days to 18 days to obtain cells. hormone.

More preferably, in the step of separating cells from pig umbilical cord tissue for subculture and obtaining cytokines, the isolated cells are cultured in serum-free medium for 12 days to obtain cytokines.

Preferably, the pig umbilical cord tissue is derived from a specific pathogen free (SPF) pig.

The present invention further provides a pharmaceutical composition for promoting hair growth comprising an effective amount of the aforementioned multi-peptide composition and adiponectin, and a pharmaceutically acceptable vehicle.

The invention further provides the use of a composition as described above for the manufacture of a medicament for promoting hair growth, wherein an effective amount of the medicament is administered to a recipient to promote hair growth of the recipient.

The invention further provides the use of a composition as described above for the manufacture of a medicament for promoting growth of hair cells, wherein an effective amount of the medicament is administered to a recipient to promote hair cell growth of the recipient.

Preferably, the composition further comprises 0.1 micromolar concentration (mM) to 100 mM minoxidil (MNX), 1 nanomolar concentration (nM) to 1000 nM vitamin D3 or a combination thereof.

More preferably, the minoxidil is 1 mM and the vitamin D3 is 10 nM.

Preferably, the composition further comprises from 1 nM to 1000 nM of vitamin D3.

More preferably, the vitamin D3 is 10 nM.

The present invention further provides a composition for promoting hair growth comprising a multi-peptide composition and vitamin D3 (vitamin D3), wherein the volume fraction of the multi-peptide composition is from 1% to 20% of the peptide composition, The vitamin D3 is from 1 nM to 1000 nM.

Preferably, the multi-peptide composition has a volume percentage of 10% polypeptide composition and the vitamin D3 is 10 nM.

The invention further provides a pharmaceutical composition for promoting hair growth comprising an effective amount of the aforementioned multi-peptide composition and vitamin D3, and a pharmaceutically acceptable carrier.

The invention further provides the use of a composition as hereinbefore described for the manufacture of a medicament for promoting hair growth, wherein administration of an effective amount of the medicament to a recipient promotes hair growth of the recipient.

Preferably, the pharmaceutical product is a region of the skin which is locally or systemically administered to the recipient to be affected by the hair loss.

More preferably, the area of the skin affected by the hair loss is scalp.

Preferably, the receptor is a human or an animal.

The compositions of the present invention may be a combination of the above-described multi-peptide composition with adiponectin and a pharmaceutically acceptable carrier, or a multi-peptide composition and vitamin D3, using techniques well known to those skilled in the art. A pharmaceutically acceptable carrier is prepared in a dosage form suitable for use in the compositions of the present invention. The "pharmaceutically acceptable carrier" as used in the present invention includes, but is not limited to, a solvent, an emulsifier, a suspending agent, a decomposer, a binding agent. , excipient, stabilizing agent, chelating agent, diluent, gelling agent, preservative, lubricant, surface activity Surfactant, and other carriers similar or suitable for use in the present invention.

The "pharmaceutical composition" of the present invention may exist in various forms including, but not limited to, liquid, semi-solid, and solid pharmaceutical forms such as solutions, emulsions, suspensions, powders. (powder), tablet, pill, lozenge, troche, chewing gum, slurry, liposome, and the like or other suitable for use in the present invention Formulation.

"Effective dose" as used herein means an amount effective to achieve a hair growth promoting effect at a dose and for a desired period of time; in accordance with the present invention, a multi-peptide composition is administered by administering a specific range of amounts. With the adiponectin, or the multi-peptide composition and the vitamin D3, the effect of hair growth can be achieved; more preferably, the effect of achieving a synergistic effect can be achieved.

The invention further provides the use of a composition as described above for the manufacture of a medicament for the treatment of alopecia, wherein an effective amount of the medicament is administered to a recipient for the treatment of receptor depilation.

The "hair loss" described in the present invention, also known as alopecia, hairlessness, or thin hair, is a general term for local or whole body hair loss, and is mainly characterized by hair removal. Baldness is a symptom of hair loss from the scalp.

According to the present invention, adiponectin or vitamin D3 is a kind of "fat-soluble compound".

An advantage of the present invention is that the present invention comprises a composition of a multi-peptide composition and adiponectin, which is effective for promoting hair growth and promoting cell growth, and a combination of a multi-peptide composition and adiponectin for promoting hair growth and promoting cells The effects of growth have a multiplier effect. Another composition comprising the multi-peptide composition and vitamin D3 of the present invention is effective for promoting hair growth, and the combination of the multi-peptide composition and vitamin D3 also has a multiplying effect on promoting hair growth.

The technical means adopted by the present invention for achieving the object are further explained below in conjunction with the drawings and the preferred embodiments of the present invention.

The preparation method of the multi-peptide composition is prepared by the Chinese Patent Application No. 103135440 "Composition for promoting the growth of dermal papilla cells and a pharmaceutical composition thereof and a preparation method thereof", and the detailed preparation method is as follows. 1 to Preparation Example 6:

Preparation Example 1 Separation of cells from pig umbilical cord

A pig umbilical cord is prepared, and the pig umbilical cord is washed with 75% ethanol for 20 seconds to 30 seconds, and then washed with PBS, and then the umbilical cord is cut into 3 to 4 aliquots and sterilized in a culture dish. Open the umbilical cord with a scalpel or forceps along the umbilical cord vein, and pull the umbilical cord apart with the umbilical cord. Carefully remove the artery to avoid any blood spilling into the Wharton's jelly. The vein is also removed. The Huatong's block was removed from the cord amnion and placed in a fresh and containing alpha-MEM dish to keep it moist. The umbilical cord of the surgical scissors is then cut into approximately 0.1 mm ³ to 100 mm ³ to form umbilical cord fragments, and 4 to 6 umbilical cord fragments are placed in a culture dish containing 10 ml of medium (α-MEM and 10). In % FBS), placed in a CO ₂ incubator (containing 5% CO ₂ ). Add 3 ml of medium twice a week. After 10 days, the umbilical cord fragments were removed, and washed with PBS and then fresh medium was added to culture the cells to 80% to 90% full, and subcultured to proliferate the cells.

Preparation 2 Subcultured cells

The medium was aspirated by a vacuum aspirator and the cells in the plate were washed with 5 ml of PBS. The PBS was again removed, and 3 ml of a concentration of 0.25% trypsin-ethylenediaminetetraacetic acid (EDTA) was added to each plate; the plate was placed at 37 ° C for 5 minutes. The separated cells were collected in a 15 ml centrifuge tube, centrifuged at 400 G for 5 minutes, and the supernatant was removed and 2 ml of the medium was added. The cells were resuspended by a pipette and 10 microliters (μl) of cells were aspirated and mixed with 10 ul of trypan blue and counted in an automated cell counter.

Preparation Example 3 Preparation of cytokines (cytokines)

To produce cytokines, the cells obtained in Preparation Example 2 were first inoculated into a cell culture dish, and grown to a density of 3 x 10 ⁵ to ⁷ x 10 ⁵ cells per dish. The cells were cultured in a CO ₂ incubator at 37 ° C and the medium was changed twice a week (approximately every 3 to 4 days) until the cells were grown to 90% full.

When the cells were 90% full, wash the cells twice with 5 ml PBS, add 8 ml of serum-free medium to each dish, and incubate for 12 days at 37 ° C in a CO ₂ incubator. Obtain cytokines.

Preparation Example 4 Collection of multi-peptide mixed solution

Some cytokines are released into the medium, while others lie in the cells. The medium was collected, and the attached cells were exposed to 3 ml and treated with 0.2% trypsin-EDTA for 5 minutes at 37 ° C. The cells were collected and centrifuged at 40 G for 5 minutes and the supernatant was removed, followed by 10 ml of PBS. The precipitated cells were washed once for 1 time. Centrifuge again and remove the supernatant, then resuspend the cells in 3 ml PBS and place in a cryotube, then immerse the cryotube containing the cells directly in liquid nitrogen. The cryotube containing the cells was thawed in a 37 ° C water bath, and the above freeze-thaw cycles were repeated twice to break the cells. The ruptured cells were centrifuged at 1000 G for 15 minutes to 20 minutes to obtain supernatant and cell lysate. Mixing the supernatant and cell lysate with a peptide mixture solution, and detecting the supernatant or multi-peptide mixed solution by enzyme-linked immunosorbent assay (ELISA) [eg, recombinant basic fibroblast growth) The concentration of a factor (basic fibroblast growth factor (bFGF) or platelet-derived growth factor (PDGF), etc.].

Preparation Example 5 Concentration and desalting of a multi-peptide mixed solution

Preparation Example 4 The peptide obtained was poured as much as ultrafiltration device (Model Amicon ^® stir cell) or centrifugal device (Amicon ^® filter centrifugation device) to reduce the volume of the multi-peptide and increasing concentrations of the mixed solution, to obtain Concentrated multi-peptide mixed solution. The concentrated multi-peptide mixed solution is placed in a collection tube by an ultrafiltration device or a centrifugal device. 2 ml of the concentrated multi-peptide mixed solution was taken to evaluate the concentration of the multi-peptide mixed solution.

Preparation Example 6 Lyophilization Polypeptide Mixture Solution

50 ml of the concentrated multi-peptide mixed solution obtained in Preparation Example 5 was placed in a zipper bag and left at -80 ° C overnight (12 hours to 16 hours). The bag containing the concentrated multi-peptide was mixed together in a freeze dryer to freeze-dry the mixture of the peptides (4 days to 5 days) to obtain a lyophilized multi-peptide mixed powder. The lyophilized multi-peptide mixed powder was resuspended in sterile water and filtered through a 0.22 μm filter membrane to obtain a multi-peptide composition, and the multi-peptide composition was stored at -80 ° C, wherein the multi-win The peptide composition comprises: 20 ng/ml to 200 ng/ml angiogenin per ml, preferably 55 ng/ml; 2 ng/ml to 20 ng/ml, preferably 6 ng/ml PDGF And 2 ng/ml to 20 ng/ml, preferably 4 ng/ml Fibroblast Growth Factor 7, FGF7.

Preparation Example 7 In vitro test for isolating hair follicles

After using BL6 mice and sacrificed, the skin containing the beard parts was removed with scissors and a scalpel and placed in PBS {containing 1% PSA [containing penicillin, streptomycin and amphotericin B ( The amphotericin B) anti-fungal antibiotic (antibiotic-antimycotic, 100X) and 0.5% amphotericin B (fungizone) were kept moist, followed by 3 washes with PBS (containing 1% PSA and 0.5% fungizone). Put the clean petri dish into a little PBS (containing 1% PSA and 0.5% fungizone), then put the skin with the beard part. The hair follicle can be seen by turning the skin containing the beard part. The hair follicles are carefully separated by using a sterile scorpion and a clean scalpel. The separated hair follicles are placed in a clean Petri dish containing PBS (containing 1% PSA and 0.5% fungizone). .

Preparation 8 Isolation and culture of hair follicle dermal papilla cells

The mouse BL6 was sacrificed and its beard-bearing skin was taken and placed overnight in PBS (containing 1% PSA and 0.5% fungizone). After separating the whole hair follicle, the end-bulb of the hair follicle was excised and cultured in the hair follicle dermal papilla cell culture medium (purchased from Promocell), the medium was changed until the cells were grown, and then the medium was changed every 2 to 3 days. .

Preparation 9 Culture of keratinocytes

Human skin tissue was taken and washed 3 times with PBS (containing 1% PSA and 0.5% fungizone). After the skin tissue is placed in a petri dish, it is surgically cut into small pieces of about 0.1 mm ³ to 100 mm ³ and the fat and connective tissue are removed. A small piece of skin tissue was prepared in a Petri dish containing 2.4 units (U/ml) of dispase (Dispase ^® II) per ml overnight at 4 ° C, and the small pieces of skin tissue were soaked in PBS every other day, and gently The dermis (pale, opaque, and viscous) was separated from the epidermis (white, translucent) of the small segment of the skin tissue by a curved forceps into a new Petri dish containing 4 ml PBS. Add 1 ml of 0.25% trypsin to the dermis containing the dermis (final concentration of 0.05% trypsin), then cut the dermis into small pieces and repeat the pipetting multiple times with a micropipette until turbidity, add 0.5 ml fetal bovine serum To stop the decomposition of trypsin. The trypsin-decomposed dermis was separated into a single cell solution by a 100 μm cell filtration device, and centrifuged at 200 G for 5 minutes in a 15 ml centrifuge tube. After removing the supernatant, the keratinocyte medium was added (purchased from Thermo Fisher Company) reconstituted the lower layer cells and planted them in a culture dish. The medium was changed every other day, and then the medium was changed every three days. The cultured cells were keratinocytes.

Example 1 Hair Growth Experiment The hair follicles prepared in Preparation Example 7 were taken as an experiment. The experiment was divided into control group [Williams medium E and 10 ng/ml corcorolone and 10 μg were added. /ml insulin], 1 mM MNX, 10 nM vitamin D3, 0.001% caffeine and 1 ng/ml adiponectin; in the above five groups, each group was subdivided into administered and unadministered volume percentage As a 10% multi-peptide composition, the multi-peptide composition prepared in Preparation Example 6 was added to each group in an amount of 10%. After each group was administered separately, 25 days of culture at 37 ° C, 5% CO ₂ and observation of whisker growth, including administration of MNX, vitamin D3, caffeine, adiponectin or polypeptide composition Each group was administered once every 3 to 4 days. Table 1. Changes in beard length on days 5 to 25 of the 10% multi-peptide composition administered and not administered to each group. -: indicates no administration; +: indicates administration.

Please refer to Figure 1 and Table 1. For the control group, add 10% multi-peptide composition, whether on day 5 or to day 25, beard growth and control group added 10% peptide composition There was no significant difference in the material; in the 1 mM MNX group, the addition of 10% polypeptide composition had a tendency to grow on the 5th to 25th day, and there was no significant increase in the whisker without the addition of 10% polypeptide composition. There was no significant difference between the control group and the control group without adding 10% peptide composition; in the 1 ng/ml adiponectin group, the addition of 10% peptide composition, whether on day 5 or to day 25, increased beard The relative lengths were significantly greater than the sum of 1 ng/ml adiponectin and 10% multi-peptide composition alone, so the combination of adiponectin and multi-peptide composition had additive effects, which had unpredictable effects. . In addition, for the 10 nM vitamin D3 group, the addition of 10% polypeptide composition on day 20, the relative length of whisker increase (43.35%) was significantly greater than the administration of 1 ng / ml adiponectin (19.68%) and The sum of the 10% multi-peptide composition (20.21%), so the combination of vitamin D3 and the multi-peptide composition has an additive effect, and an unexpected effect is obtained. Table 2. Changes in beard length on days 5 to 10 for each group administered with and without the 10% polypeptide composition. -: indicates no administration; +: indicates administration.

Please refer to Figure 2 and Table 2. For the 1 ng/ml adiponectin group, add 10% multi-peptide composition, whether on day 5 or day 10, the relative length of beard increase (23.05) %, 50.12%) were significantly greater than the sum of 1 ng/ml adiponectin (3.08%, 5.30%) and 10% multi-peptide composition (11.06%, 16.25%), so adiponectin and multi-win The combination of peptide compositions has an additive effect and an unexpected effect is obtained. It is worth noting that in the 0.001% caffeine group, the addition of 10% polypeptide composition, whether on day 5 or day 10, resulted in inhibition of whisker growth compared to 0.001% caffeine alone. The opposite direction (teaching away).

Example 2 Dermal papilla cell proliferation experiment

The dermal papilla cells of Preparation Example 8 were seeded in a 96-well plate at a rate of 3 x 10 ³ per well, and 0.1 ml of hair follicle dermal papilla cell culture medium was added to each well. After the medium was removed every other day, a new hair follicle dermal papilla cell culture medium was added. The experiment was divided into control group (only hair follicle dermal papilla cell culture medium), volume percentage 1% to 10% peptide composition, 0.1 mM to 100 mM MNX, 1 nM. Up to 1000 nM vitamin D3, volume percentage 0.0002% to 0.025% caffeine, and 0.1 ng/ml to 100 ng/ml adiponectin. After 72 hours, the cell growth was quantified by cell activity assay (MTS reagent was purchased from Promega's CellTiter 96 ^® AQueous One Solution Cell Proliferation Assay). Add 20 μl of AQueous One reagent (CellTiter 96 ^® AQueous one solution reagent) to a 96-well plate containing 100 μl of medium per well and treated in different groups at 37 ° C in a 5% CO ₂ incubator After standing for 2 hours, the absorbance was measured at 490 nm with a spectrophotometer to detect the proliferation of viable cells. Table 3. The survival status of dermal papilla cells on day 3 of each group at different concentrations.

Referring to Figure 3 and Table 3, the individual doses of different concentrations were tested to find out the range of doses that each group can withstand for dermal papilla cells, and the appropriate dose for the following experiment was selected.

The dermal papilla cells of Preparation Example 8 were also planted in a 96-well plate at a rate of 3 x 10 ³ per well, and 0.1 ml of hair follicle dermal papilla cell culture medium was added to each well. After the medium was removed every other day, a new hair follicle dermal papilla cell culture medium was added. The experiment was divided into control group (only hair follicle dermal papilla cell culture medium), 1 ng/ml adiponectin, 1 ng/ml adiponectin and 1 mM MNX. And 1 ng/ml adiponectin, 1 mM MNX, 10 nM vitamin D3; in the above four groups, each group is subdivided into administered and not administered 10% multi-peptide composition, the 10% multi-peptide composition The multi-peptide composition prepared in Preparation Example 6 was added to each group in an amount of 10%. After 72 hours, the cell growth was quantified by cell activity assay (MTS Assay, supra) to detect the proliferation of viable cells. Table 4. Survival status of dermal papilla cells on day 3 of each group administered with and without administration of 10% polypeptide composition.

Referring to Figure 4 and Table 4, in the 1 ng/ml adiponectin group, the percentage difference in survival of dermal papilla cells was (105.04%) after the addition of 10% polypeptide composition, which was significantly greater than that of the single administration. The sum of 1 ng/ml adiponectin (5.42%) and 10% polypeptide composition (78.94%), so the combination of adiponectin and polypeptide composition has the effect of promoting the growth of dermal papilla cells. Unexpected effects.

In addition, in the case of 1 ng/ml adiponectin and 1 mM MNX, the percentage difference in survival of dermal papilla cells was (120.30%) after the addition of 10% polypeptide composition, which was also significantly greater than 1 ng administered alone. The sum of ml adiponectin with 1 mM MNX (15.51%) and 10% polypeptide composition (78.94%); for 1 ng/ml adiponectin and 1 mM MNX and 10 nM vitamin D3, combined addition After 10% polypeptide composition, the percentage difference in survival of dermal papilla cells was (107.94%), which was also significantly greater than 1 ng/ml adiponectin alone and 1 mM MNX and 10 nM vitamin D3 (0.76%) and 10%. The sum of the multi-peptide compositions (78.94%). Therefore, in addition to the combination of adiponectin and multi-peptide composition, the addition of MNX, or the simultaneous addition of MNX and vitamin D3 have the effect of promoting cell growth.

Example 3 Keratinocyte proliferation experiment

After coating with a coating matrix for more than 30 minutes before the 96-well plate, the keratinocytes of Preparation Example 9 were planted in a 96-well plate at a rate of 3×10 ³ per well, and 0.1 ml of keratinocyte medium was added per well and Human keratinocyte growth supplement (HKGS, purchased from Thermo Fisher). New keratinocyte culture medium was added after removing the medium every other day. The experiment was divided into control group (keratinocyte culture medium only), 0.001% caffeine, and 1 ng/ml adiponectin. In the above three groups, each group was subdivided into The 10% multipeptide composition was administered without addition, and the multi-peptide composition prepared in Preparation Example 6 was added to each group to an amount of 10%. After 72 hours, the cell growth was quantified by cell activity assay (MTS Assay, same as in Example 2 above) to detect the proliferation of viable cells. Table 5, keratinocyte survival status on day 3 of each group administered and not administered 10% multi-peptide composition.

Referring to Figure 5 and Table 5, for the 1 ng/ml adiponectin group, the percentage difference in keratinocyte survival was (9.89%) after the addition of 10% multi-peptide composition, which was significantly greater than that of 1 alone. The sum of ng/ml adiponectin (5.10%) and 10% multi-peptide composition (1.01%), so the combination of adiponectin and multi-peptide composition has the effect of promoting the growth of keratinocytes, and it is impossible to Expected efficacy. It is worth noting that in the 0.001% caffeine group, the addition of a 10% polypeptide composition resulted in a reverse teaching of inhibiting keratinocyte growth compared to the addition of 0.001% caffeine alone.

It is apparent to those skilled in the art that various modifications and variations can be made without departing from the scope and spirit of the invention. Although the present invention has been described in terms of specific preferred embodiments, it should be understood that the invention should not be In fact, the various modifications that are apparent to those skilled in the art are also contemplated by the scope of the invention.

Figure 1 is a bar graph of the composition of the present invention for the 5th to 25th day of the hair growth experiment; "-" means that 10% of the peptide composition is not administered; "+" means that 10% is awarded. Peptide composition; MNX is minoxidil (abbreviation of minoxidil). Figure 2 is a bar graph of the composition of the present invention for the 5th and 10th day of the hair growth experiment; "-" means that 10% of the peptide composition was not administered; "+" means that 10% of the victory was administered. Peptide composition; MNX is minoxidil. Figure 3 is a bar graph of the multi-peptide composition, minoxidil, vitamin D3, caffeine and adiponectin in dermal papilla cell survival assays at various concentrations. Figure 4 is a bar graph of the composition of the present invention for dermal papilla cell survival test; "-" means that 10% of the peptide composition was not administered; "+" means that 10% of the peptide composition was administered; MNX For Minoxidil. Figure 5 is a bar graph of the composition of the present invention for keratinocyte survival test; "-" means that 10% of the peptide composition was not administered; "+" means that 10% of the peptide composition was administered; Minoxidil.

Claims (9)

A composition for promoting hair growth comprising a multi-peptide composition and a fat-soluble compound, wherein the fat-soluble compound is adiponectin or vitamin D3; the composition comprises 1% to 20% by volume a multi-peptide composition, the adiponectin is 0.1 ng/ml to 100 ng/ml per ml, the vitamin D3 is 1 nanomolar (nM) to 1000 nM, and the multi-peptide composition is Based on the volume of the multipeptide composition, comprising 20 ng/ml to 200 ng/ml of angiogenin, 2 ng/ml to 20 ng/ml of platelet-derived growth factor (PDGF) and 2 ng /ml to 20 ng/ml of fibroblast growth factor 7 (FGF7). The hair growth promoting composition according to claim 1, wherein the composition comprises a 10% by volume multi-peptide composition and 1 ng/ml of adiponectin. The hair growth promoting composition according to claim 1, wherein the composition comprises 10% by volume of a multi-peptide composition and 10 nM of vitamin D3. A use of a composition according to any one of claims 1 to 3 for the manufacture of a medicament for promoting hair growth, wherein an effective amount of the medicament is administered to a recipient to promote hair growth of the recipient. A use of a composition comprising a multi-peptide composition and adiponectin for the preparation of a medicament for promoting growth of hair cells, wherein an effective amount of the medicament is administered to a recipient to promote hair cell growth of the recipient; The composition comprises a multi-peptide composition having a volume percentage of from 1% to 20%, the adiponectin is from 0.1 ng/ml to 100 ng/ml, and the multi-peptide composition has a volume of the multi-peptide composition The reference comprises 20 ng/ml to 200 ng/ml of angiogenin, 2 ng/ml to 20 ng/ml of platelet-derived growth factor, and 2 ng/ml to 20 ng/ml of fibroblast growth factor 7. The use according to claim 5, wherein the multi-peptide composition has a volume percentage of 10% and the adiponectin is 1 ng/ml. The use of claim 5, wherein the composition further comprises 0.1 micromolar (μM) to 100 μM minoxidil (MNX). The use of claim 7, wherein the minoxidil is 1 μM. The use of any one of claims 5 to 8, wherein the composition further comprises from 1 nM to 1000 nM of vitamin D3.